Oak Thistle LLC Makes New $940,000 Investment in Stryker Corporation $SYK

Oak Thistle LLC bought a new stake in shares of Stryker Corporation (NYSE:SYK) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,544 shares of the medical technology company’s stock, valued at approximately $940,000.

A number of other institutional investors also recently bought and sold shares of the stock. Two Point Capital Management Inc. purchased a new position in Stryker during the 2nd quarter valued at about $7,281,000. Alecta Tjanstepension Omsesidigt increased its stake in shares of Stryker by 82.0% during the second quarter. Alecta Tjanstepension Omsesidigt now owns 458,300 shares of the medical technology company’s stock valued at $181,235,000 after purchasing an additional 206,500 shares in the last quarter. SVB Wealth LLC purchased a new position in shares of Stryker during the second quarter valued at approximately $4,785,000. AXQ Capital LP bought a new stake in shares of Stryker in the 2nd quarter worth approximately $567,000. Finally, United Services Automobile Association bought a new stake in shares of Stryker in the 1st quarter worth approximately $2,857,000. 77.09% of the stock is owned by institutional investors.

Stryker Price Performance

Shares of SYK opened at $353.03 on Friday. The firm has a fifty day simple moving average of $365.45 and a two-hundred day simple moving average of $377.69. The firm has a market cap of $135.01 billion, a PE ratio of 46.39, a P/E/G ratio of 2.50 and a beta of 0.89. The company has a current ratio of 1.85, a quick ratio of 1.13 and a debt-to-equity ratio of 0.68. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. Stryker had a return on equity of 24.07% and a net margin of 12.07%.Stryker’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, equities analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Wednesday, December 31st will be paid a $0.88 dividend. This is a boost from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date is Wednesday, December 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s dividend payout ratio (DPR) is currently 44.15%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Evercore ISI lowered their price objective on Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research note on Friday, October 31st. BTIG Research restated a “buy” rating and set a $410.00 price objective on shares of Stryker in a research note on Friday, November 14th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Stryker in a report on Monday. Royal Bank Of Canada reiterated an “outperform” rating and set a $435.00 price target on shares of Stryker in a report on Friday, November 14th. Finally, Wells Fargo & Company raised their price target on shares of Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. Twelve investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $431.39.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the transaction, the director directly owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Preston Wendell Wells sold 165 shares of Stryker stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the transaction, the chief financial officer owned 6,694 shares in the company, valued at $2,449,200.72. This represents a 2.41% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 522,118 shares of company stock worth $185,381,932 in the last quarter. Company insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.